Tezspire® (tezepelumab-ekko)

Tezspire (tezepelumab‑ekko) is covered only as FDA‑approved add‑on maintenance therapy for severe asthma in patients ≥12 years and is not covered for other indications. Initial approval (6 months) requires ≥3 months of prior inhaled corticosteroid plus another controller, objective evidence of uncontrolled asthma (e.g., ≥2 steroid‑requiring exacerbations in the past year, or ≥1 hospitalization/ER/urgent care, or FEV1 <80% predicted, or FEV1/FVC <0.80, or worsening with OCS taper) and prescription by/consultation with an allergist, immunologist, or pulmonologist; renewal (12 months) requires ≥6 months of Tezspire, continued ICS use, documented clinical response, and dosing per label (210 mg SC every 4 weeks).

"Add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.